2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5192 Ziftomenib combined with venetoclax/azacitidine in newly diagnosed NPM1-m acute myeloid leukemia (AML): Long-term results from KOMET-007

James Stewart Blachly, MD, Amir T. Fathi, MD2, Eunice Sue Wang, MD3, Guru Subramanian Guru Murthy, MD4, Gail J Roboz, MD5, Harry P. Erba, MD6, Keith W. Pratz, MD7, Kiran Naqvi8, Stephen A. Strickland, MD9, Clark Clark Alsfeld, MD10, Neil D Palmisiano, MD, MS11, Jessica K. Altman, MD12, Ghayas C. Issa, MD13, Yazan F. Madanat, MD14, Ayman Qasrawi, MD15, Tara L. Lin, MD16, Anjali Sunder Advani, MD17, James K. Mangan, MD18, Gary J. Schiller, MD19, Talha Badar, MD20, Suresh Kumar Balasubramanian, MD21, Marcello Rotta22, Ivana Gojo, MD23, Mohamad Khawandanah, MD24, Marina Kremyanskaya, MD, PhD25, Michael Schuster, MD26, Grerk Sutamtewagul, MD27, Cecilia Arana Yi, M.D.28, Hongling Zhang, MS29, Tianle Chen, PhD30, Harris Soifer, PhD31, Valerie Chamberlain Santos32, Robert Sutphin, MD33, Marcie Riches, MD, MS34, Daniel Corum, PhD35, Mollie Leoni, MD36, Amer M. Zeidan, MD37
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, New York, United States
6 Duke Cancer Institute, Durham, North Carolina, United States
7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Division of Hematology and Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, United States
9 SCRI at TriStar Centennial, Nashville, Tennessee, United States
10 Ochsner Health, New Orleans, Louisiana, United States
11 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
12 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
13 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas Southwestern Medical Center, Dallas, Texas, United States
15 Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, United States
16 University of Kansas, Fairway, Kansas, United States
17 Taussig Cancer Institute, Cleveland, Ohio, United States
18 University of California, San Diego, California, United States
19 David Geffen School of Medicine at UCLA, Los Angeles, California, United States
20 Mayo Clinic, Jacksonville, Florida, United States
21 Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
22 Colorado Blood Cancer Institute, Denver, Colorado, United States
23 Johns Hopkins University, Baltimore, Maryland, United States
24 Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
25 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
26 Stony Brook University Cancer Center, Stony Brook University Renaissance Medical School, Stony Brook, New York, United States, Stony Brook University Cancer Center, Stony Brook University Renaissance Medical School, Stony Brook, New York, United States
27 University of Iowa Health Care, Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
28 Mayo Clinic, Phoenix, Arizona, United States
29 Kura Oncology, Inc., San Diego, California, United States
30 Kura Oncology, Inc., San Diego, California, United States
31 Kura Oncology, Inc., San Diego, California, United States
32 Kura Oncology, Inc., San Diego, California, United States
33 Kura Oncology, Inc., San Diego, California, United States
34 Kura Oncology, Inc., San Diego, California, United States
35 Kura Oncology, San Diego, California, United States
36 Kura Oncology, Inc., San Diego, California, United States
37 Department of Internal Medicine, Section of Hematology, Yale University, New Haven, Connecticut, United States

Introduction: NPM1 mutations drive leukemogenesis in ~30% of AML. Ziftomenib is a potent, selective, oral menin inhibitor approved as monotherapy for adults with relapsed/refractory NPM1-mutated (NPM1-m) AML and has also shown encouraging clinical activity in combination for newly diagnosed (ND) NPM1-m or KMT2A-r AML. KOMET-007 (NCT05735184) is an ongoing, open-label, phase 1a/b dose-escalation/expansion study of ziftomenib in combination with standard chemotherapies in NPM1-m or KMT2A-r AML. Here we report long-term outcomes in patients with ND NPM1-m AML treated with ziftomenib 600 mg once daily combined with venetoclax/azacitidine (Ven/Aza) from phase 1b of KOMET-007.

Methods: Adults (≥18y) with ND NPM1-m AML ineligible for intensive chemotherapy were enrolled in phase 1b. Ziftomenib 600 mg was orally administered once daily continuously starting on Cycle 1 Day 8, with standard doses of Ven/Aza starting on Cycle 1 Day 1. This staggered approach has been shown to reduce the rate and potential severity of differentiation syndrome (DS). Phase 1b primary endpoints were adverse events (AEs) and complete remission (CR; ELN 2022) rate. Secondary endpoints included composite CR (CRc; CR with full/partial/incomplete hematologic recovery) rate, overall response rate (ORR) and duration of response. Measurable residual disease (MRD) was assessed locally per institutional standards and centrally for NPM1 by next-generation sequencing.

Results: As of April 10, 2026, 40 patients with ND NPM1-m AML were enrolled and treated. Median age was 75y (range 53–93), 53% were female, 58% had ECOG PS 2; 35% had FLT3 co-mutations and 30% had IDH co-mutations. Median follow-up was 11.2 months (range 0.4–19.0). Grade (Gr)≥3 treatment-emergent AEs occurred in 34 patients (85%), most commonly neutropenia (38%), leukopenia (33%), thrombocytopenia (28%) and anemia (25%). Gr≥3 ziftomenib-related AEs occurred in 16 patients (40%), most commonly neutropenia (18%) and thrombocytopenia (18%). One patient (3%) had DS (Gr2), which resolved successfully with protocol-specified mitigation. Investigator-assessed QTc prolongation occurred in 3 patients (8%; 1 Gr2, 2 Gr3); one event was considered ziftomenib-related. These events occurred in the setting of concomitant use of QT-prolonging antimicrobials and electrolyte abnormalities; all events resolved with electrolyte repletion and all patients continued on/resumed ziftomenib.

At time of data cutoff, CR rate was 75% (30/40) and ORR was 88% (35/40). CRc rate was 85% (34/40) with a median time to CRc of 3.2 wks (range 2.4–12.1). Among evaluable CRc responders, 72% (23/32) achieved local NPM1 MRD negativity, with a median time to first MRD negativity of 9.9 weeks (range 2.9–28.1) or ~2 cycles. At sensitivity thresholds of <10-3 and <10-4, central NPM1 MRD negativity rates were 68% (17/25) and 44% (11/25), respectively, with median times to first MRD negativity of 9.4 (range 4.9–22.9) and 9.6 (range 8.4–22.9) weeks. Among CRc responders, median time to neutrophil recovery ≥1×109/L was 37 days and to platelet recovery ≥100×109/L was 30 days. Median duration of CRc and median overall survival (OS) were not reached after median follow-up times of 9.7 and 14.3 months, respectively; the 12-month OS rate was 64% (95% CI 45.4–77.0). Six patients underwent hematopoietic stem cell transplantation (HSCT), 5 of whom proceeded to ziftomenib maintenance therapy. An additional 10 patients transitioned to maintenance therapy without HSCT. The study is ongoing with 55% (22/40) of patients still on-study and 43% (17/40) on ziftomenib treatment at time of data cutoff. Updated safety and clinical activity results will be presented.

Conclusions: In the ongoing KOMET-007 study, ziftomenib 600 mg once daily combined with Ven/Aza was well tolerated and demonstrated robust clinical activity in ND NPM1-m AML. This regimen resulted in an 85% CRc after a median of 3.2 weeks and 72% CRc MRD negativity (local) after a median of 9.9 weeks (~2 cycles). This combination led to low rates of ziftomenib-related cytopenias and no apparent additional myelosuppression. One DS and three investigator-assessed QTc prolongation events resolved. Median duration of CRc and median OS were not reached, with 12-month OS rate of 64%. Together these data support continued evaluation of this ziftomenib-based low-intensity combination in the KOMET-017 (NCT07007312) global randomized phase 3 study in ND NPM1-m AML.

James Stewart Blachly, MD: Syndax - Honoraria; Astellas - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony)